Core antigen · SINGLE PROTEIN · Hepatitis B virus
This target will appear in recent viewed items on this browser. Use the demo workspace to preview watch rules and decision queues.
Move to another high-traffic target or paste a specific ChEMBL target ID.
Structured disease, protein, and project context should read before the lower-level identity rail.
As of 2026-09-14Core antigen shows clinical signal disease relevance led by chronic hepatitis B virus infection. 5 more disease programs remain visible in the same review block. 2 linked drugs keep the current disease frame grounded. Protein identity stays anchored to UniProt Q03732. Start with chronic hepatitis B virus infection, then reuse UniProt Q03732 as the stable protein anchor across project notes and exports.
Start with chronic hepatitis B virus infection, then reuse UniProt Q03732 as the stable protein anchor across project notes and exports.
Core antigen shows clinical signal disease relevance led by chronic hepatitis B virus infection. 5 more disease programs remain visible in the same review block. 2 linked drugs remain visible in the same block.
Start review with chronic hepatitis B virus infection because it currently carries clinical signal support. Linked drugs include BERSACAPAVIR, VEBICORVIR. This disease block keeps the Open Targets-ready contract explicit while current evidence comes from ChEMBL mechanism and indication mappings.
Disease source · ChEMBL drug mechanism + indication proxyCapsid protein
Review this target as Core antigen, mapped to UniProt Q03732. ChEMBL maps the protein component as Capsid protein. Sequence length is 230 aa.
Protein source · UniProt accession via ChEMBL component mappingKeep the review anchor, source IDs, and context contract aligned before reusing this target elsewhere.
This review treats Core antigen as ChEMBL target CHEMBL1075091, mapped to UniProt Q03732. Disease framing currently uses the Open Targets-ready proxy contract.
Reuse the same identifiers in notes, watch rules, exports, and review packs so provenance stays stable across surfaces.
Choose the first block or source based on the question you are trying to answer.
Start here when your first question is whether Core antigen is the right protein anchor across sources, using UniProt Q03732 as the stable mapping.
Jump to Protein ContextUse this block first when you need to confirm why chronic hepatitis B virus infection is currently framed as clinical signal support. It currently carries 2 linked drugs in the same disease frame.
Jump to Disease ContextOpen the one-page evidence card when you want the rationale, activity base, and attribution together.
Open Review-ready CardVerify identity, organism, and the fastest next research jumps from the same page.
| Preferred Name | Core antigen |
| Target Type | SINGLE PROTEIN |
| Organism | Hepatitis B virus |
| UniProt | Q03732 |
Reviewable protein naming and mapping context for this target snapshot.
| Protein Label | Capsid protein |
| UniProt Accession | Q03732 |
| Component Type | Protein |
| Sequence Length | 230 aa |
Capsid protein
Review this target as Core antigen, mapped to UniProt Q03732. ChEMBL maps the protein component as Capsid protein. Sequence length is 230 aa.
Open Targets-ready disease context using the current target-indication evidence contract.
Core antigen shows clinical signal disease relevance led by chronic hepatitis B virus infection. 5 more disease programs remain visible in the same review block.
Start review with chronic hepatitis B virus infection because it currently carries clinical signal support. Linked drugs include BERSACAPAVIR, VEBICORVIR. This disease block keeps the Open Targets-ready contract explicit while current evidence comes from ChEMBL mechanism and indication mappings.
| ChEMBL ID | pChEMBL | Type | Value (nM) | Phase |
|---|---|---|---|---|
| CHEMBL5314362 | 9.62 | EC50 | 0.24 | Approved |
| CHEMBL3742114 | 9.0 | EC50 | 1.0 | Preclinical |
| CHEMBL5187151 | 8.8 | EC50 | 1.6 | Preclinical |
| CHEMBL4077913 | 8.7 | EC50 | 2.0 | Preclinical |
| CHEMBL4587268 | 8.7 | EC50 | 2.0 | Preclinical |
| CHEMBL5091507 | 8.57 | EC50 | 2.7 | Preclinical |
| CHEMBL4064672 | 8.52 | EC50 | 3.0 | Preclinical |
| CHEMBL4078766 | 8.52 | EC50 | 3.0 | Preclinical |
| CHEMBL4446995 | 8.52 | EC50 | 3.0 | Preclinical |
| CHEMBL4577679 | 8.52 | EC50 | 3.0 | Preclinical |
| BAO Format | Assays | Compounds | Avg pChEMBL |
|---|---|---|---|
| cell-based format | 80 | 304 | 6.8 |
| single protein format | 7 | 11 | 5.9 |
| assay format | 2 | 0 | — |